Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central anxious program, conolidine modulates alternate molecular targets. A Science Improvements research identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabilit... https://nealev086pqr6.wikifordummies.com/user